Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Obinutuzumab + Venetoclax & Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Venetoclax + obinutuzumab significantly extended progression-free survival compared with both chemoimmunotherapy and venetoclax + rituximab in previously untreated, fit patients with Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL)
Fürstenau et al. 2024 The Lancet Oncology 25(6): 744-759

An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia (CLL)
Salvaris & Opat 2021 Future Oncology 17: 371–387
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year followup from a multicentre, open-label, randomised, phase 3 trial
Fürstenau et al. 2024 The Lancet Oncology 25(6): 744-759
Venetoclax & Obinutuzumab in Pts with CLL & Coexisting Conditions
Fischer et al. 2019 N Engl J Med 380: 2225-2236
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Al-Sawaf et al. 2020 The lancet Oncology 21: 1188-1200

7/1/2026